Gamma Delta T Cell Cancer Therapy Market is segmented By Cancer Type (Lung Cancer, Leukemia, Breast Cancer, Colorectal Cancer), By Drug (ADI-001s, LAVA-051, INB-200), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023- 2030.
Gamma Delta T Cell Cancer Therapy Market Overview
The gamma delta t cell cancer therapy market is estimated to reach a high CAGR during the forecast period 2023- 2030.
The gamma delta T cells, especially the Vγ9Vδ2 T cell subset, can overcome many problems in cancer therapy, especially for tumors with no known treatment, lacking tumor-specific antigens for targeting by antibodies and CAR-T, or unresponsive to immune checkpoint inhibitors.
Gamma Delta T Cell Cancer Therapy Market Scope
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Cancer Type, By Drug, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Gamma Delta T Cell Cancer Therapy Market Dynamics
Increasing prevalence of cancer and increased research and development will drive the Gamma Delta T Cell Cancer Therapy Market
The increasing prevalence of cancer will drive the gamma delta t cell cancer therapy market in the forecast period
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Multiple myeloma is not common cancer. This year, an estimated 34,920 adults (19,320 men and 15,600 women) in the United States will be diagnosed with multiple myeloma. It is estimated that 12,410 deaths (6,840 men and 5,570 women) from this disease will occur this year. The 5-year survival rate tells what percent of people live at least five years after the cancer is found. Percent means how many out of 100. The overall 5-year rate of survival for people with multiple myeloma is 54%. For the 5% of diagnosed people at an early stage, the 5-year survival rate is 75%. If cancer has spread to a distant part of the body, the 5-year survival rate is 53%. Approximately 95% of cases are diagnosed at this stage.
To treat some kinds of leukemias and lymphomas, as well as multiple myeloma CAR T-cell therapies are FDA approved. CAR T-cell therapy is typically used after other types of treatment have been tried. γδ T cells play uniquely important roles in stress surveillance and immunity for infections and carcinogenesis.
Increased research and development will drive the gamma delta t cell cancer therapy market in the forecast period
Due to their unique role in immunosurveillance and potent anti-tumor activity, recently γδ T cells have gained considerable attention as an attractive tool for adoptive cancer immunotherapy. The remarkable success of engineered T cells for the treatment of hematological malignancies has revolutionized the field of adoptive cell immunotherapy. Accordingly, major efforts are underway to translate this exciting technology to the treatment of solid tumors and the development of allogeneic therapies. The unique features of γδ T cells, including their major histocompatibility complex (MHC)-independent anti-cancer activity, tissue tropism, and multivalent response against a broad spectrum of the tumors, render them ideal for designing universal ‘third-party’ cell products, with the potential to overcome the challenges of allogeneic cell therapy.
Their low physiological frequency has hindered the broad application of γδ T cells for adoptive cell immunotherapy in the periphery and the difficulty of ex vivo expansion. Currently considerable efforts are devoted to developing suitable methods for obtaining clinical numbers of γδ T cells. The expansion strategy of γδ T cells can be bimodal ex vivo and in vivo. In the first, γδ T lymphocytes are isolated from peripheral blood mononuclear cells (PBMCs) and stimulated ex vivo using synthetic phosphoantigen (pAg) or bisphosphonates (BP) such as zoledronic acid. Advancement in the isolation and expansion of γδ T cells, as well as optimization strategies via genetic engineering approaches, paves the way to add γδ T cells to the growing armory of cancer immunotherapeutics. It will be exciting to see the effectiveness of different approaches of γδ T cell immunotherapy in clinical trials, especially ‘off-the-shelf’ cell products, over the coming years.
Side effects associated with the gamma delta t cell cancer therapy will hamper the market
In renal cancer, mainly depending on the TCR and the NKG2D receptor gamma delta t cells display a selective lytic potential toward autologous primary renal cancer cells, but not against normal renal cells. This lytic activity involves the perforin-granzyme pathway. In an in vitro study of neck and head squamous carcinomas, perforin-granzyme lytic activity was also derived from γδ T cells. Through the ligands TRAIL and FasL second, γδ T cells can eliminate cancer cells. If TRAIL is blocked, γδ T cell-mediated cytotoxicity activity is reduced. Upregulation of Fas on osteosarcoma cells reportedly results in enhanced susceptibility of the cells to γδ T cell lysis.
Finally, γδ T cells can induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. In vitro expanded γδ T cells can enhance NK cell cytotoxicity to NK-resistant cancers. This enhanced NK cell cytolysis requires immobilized human IgG1 and co-stimulation between CD137 expressed on NK cells, and CD137L expressed on γδ T cells.
COVID-19 Impact Analysis
Due to several protocols medical practices have been affected during the COVID 19 pandemic. The procedures for diagnosis and monitoring cancer-related problems involved in this pandemic have been affected. As people are scared to undergo therapies for cancer due to the risk of COVID-19, there has been an impact on the Gamma Delta T Cell Cancer Therapy Market
Gamma Delta T Cell Cancer Therapy Market Segment Analysis
The lung cancer segment will dominate the gamma delta t cell cancer therapy market
Worldwide,one of the leading cause of cancer deaths is lung cancer. There are several reports that γδ T cells can recognize and kill lung cancer cells. By analysis of tumor-infiltrating lymphocytes (TIL), γδ T cells were detected at human lung cancer; both Vδ1+ and Vδ2+ TILs killed the N592 lung cancer cell line (31). It has been reported that Vγ9Vδ2 T cells stimulated by synthetic phosphoantigen BrHPP lysed tumor cell lines, including a primary NSCLC cell line (lung-ca 459).
Zoledronate-activated γδ T cells recognized and killed these lung cancer cell lines irrelevant to their histology, mutated genes, and sensitivity to chemotherapeutic drugs. These results support the idea that γδ T cells can be used in immunotherapy for lung cancer.
ADI-001 drug has dominated the gamma delta t cell cancer therapy market
ADI-001 is investigational immunotherapy composed of allogeneic gamma delta T cells evaluated as a potential treatment for patients diagnosed with B cell malignancies are refractory or who have relapsed to at least two prior regimens. This first-in-human study will assess the tolerability and safety of ADI-001 and is designed to determine the maximum tolerated dose (MTD) or optimal dose. Patients will be administered a single infusion of ADI-001 cells. A combination of ADI-001 and interleukin (IL)-2 may also be evaluated after the MTD or optimal dose has been determined for the single agent.
On March 10, 2021, Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that it had initiated its First-in-Human Phase I clinical trial evaluating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL). ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20, engineered to potentially enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Gamma Delta T Cell Cancer Therapy Market Geographical Share
North America region will dominate the gamma delta t cell cancer therapy market
Rising incidences of cancer and increased government initiatives to promote novel therapies will drive the Gamma Delta T Cell Cancer Therapy Market
The rate of new cases of cancer (cancer incidence) is 442.4 per 100,000 men and women per year (based on 2013–2017 cases). The cancer death rate (cancer mortality) is 158.3 per 100,000 men and women per year (based on 2013–2017 deaths).
AGT has an innovative immuno-oncology program and U.S. patents protecting its ImmunoTox viral vector platform that harnesses the power of gamma delta (γδ) T cells to revolutionize cancer therapy. The ImmunoTox vector re-programs tumor cells to become potent stimulators of γδ T cells. The activated γδ T cells are highly effective killers of tumor cells and may circulate through the blood to find and kill secondary tumors or metastases. The components of γδ T cells and how AGT’s ImmunoTox vector approach is unique in developing cancer gene therapy.
A biopharmaceutical company Incysus Therapeutics, Inc., focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that the U.S. Food and Drug Administration (FDA) had approved the Investigational New Drug (IND) application for the clinical study of a genetically modified γδ T cell in combination with chemotherapy for the treatment of patients with newly-diagnosed glioblastoma (GBM). This approval will allow Incysus to initiate a first-in-human Phase 1 clinical trial of gene-modified γδ T cells for cancer immunotherapy.
Gamma Delta T Cell Cancer Therapy Market Companies
Major key players in the gamma delta t cell cancer therapy market are Acepodia, Adaptate Therapeutics, Adicet, Cytomed Therapeutics, Gadeta, GammaDelta Therapeutics, IN8bio, Kiromic Biopharma, Lava Therapeutics, Takeda Pharmaceuticals, TC Biopharm
Key Companies
GammaDelta Therapeutics
Overview: GammaDelta Therapeutics is the UK headquartered biotechnology company founded upon world-class academic research conducted by Professor Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute Cancer Research Technology. The company aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with hematological malignancies and solid tumors.
Product Portfolio: GammaDelta Therapeutics is the only company with the capability to generate both blood-and tissue-derived allogeneic immunotherapies based on Vδ1+ T cells with the potential to provide additional patient benefit in the treatment of hematological malignancies and solid tumors.
Key Development: On May 20, 2021, GammaDelta Therapeutics, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy announced the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug (IND) application for GDX012 a allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy.It is to be investigated as a treatment for hematological malignancies. The FDA also granted orphan drug designation to allogeneic Vδ1 γδ T cell therapy (GDX012) to treat Acute Myeloid Leukaemia (AML).
The gamma delta t cell cancer therapy market report would provide an access to an approx. 53 market data table, 43 figures and 200 pages.
